Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k).
Farr A, Effendy I, Frey Tirri B, Hof H, Mayser P, Petricevic L, Ruhnke M, Schaller M, Schaefer APA, Sustr V, Willinger B, Mendling W.
Mycoses. 2021 Jun;64(6):583-602. doi: 10.1111/myc.13248. Epub 2021 Feb 27.
Candidiasis (vulvovaginal).
Martin Lopez JE.
BMJ Clin Evid. 2015 Mar 16;2015:0815.
Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.
Martens MG, Maximos B, Degenhardt T, Person K, Curelop S, Ghannoum M, Flynt A, Brand SR.
Am J Obstet Gynecol. 2022 Dec;227(6):880.e1-880.e11. doi: 10.1016/j.ajog.2022.07.023. Epub 2022 Jul 19.
Acute vulvovaginitis.
Shirley RL.
N Engl J Med. 2006 Dec 28;355(26):2791; author reply 2791. doi: 10.1056/NEJMc062854.
Ibrexafungerp to treat acute vulvovaginal candidiasis.
Masone MC.
Nat Rev Urol. 2021 Nov;18(11):638. doi: 10.1038/s41585-021-00522-9.
Candidiasis (vulvovaginal).
Spence D.
BMJ Clin Evid. 2010 Jan 5;2010:0815.
Idiopathic granulomatous vulvitis.
Rowan DM, Jones RW.
Australas J Dermatol. 2004 Aug;45(3):181-3. doi: 10.1111/j.1440-0960.2004.00085.x.
Pharmacological treatment of acute vulvovaginal candidiasis.
Higgins SP, Woolley PD.
Int J STD AIDS. 1993 Sep-Oct;4(5):261-5. doi: 10.1177/095646249300400503.
Vulvovaginal candidosis.
Kinghorn GR.
J Antimicrob Chemother. 1991 Jul;28 Suppl A:59-66. doi: 10.1093/jac/28.suppl_a.59.
Beyond fluconazole: A review of vulvovaginal candidiasis diagnosis and treatment.
Hellier SD, Wrynn AF.
Nurse Pract. 2023 Sep 1;48(9):33-39. doi: 10.1097/01.NPR.0000000000000095.
